Abstract

CONVALESCENT PLASMA FOR MANAGEMENT OF COVID-19: A SYSTEMATIC REVIEW

Ahalya Krishnan*, Sowparnika Treasa Sabu and Prof. (Dr.) Shaiju S. Dharan

Abstract

Background: The purpose of the current study is to evaluate the efficacy of convalescent plasma therapy in the prevention and management of COVID-19. Published clinical studies on the use of plasma convalescent therapy for COVID-19 have been reviewed. Method: An extensive search was performed in PubMed, CDSR, NHS Evidence, NIHR-HTA, WHO Global Index Medicus, and clinicaltrials. gov until end of August23, 2020. The systematic review was performed in accordance with PRISMA guidelines, articles were screened manually and the related studies were finally included. Results: From extensive electronic database and literature search, and screening using PRISMA guidelines, 9 studies were included in the review. The studies were assessed for effectiveness of convalescent plasma (CP) therapy in reducing viral RNA load and improving the mortality and quality of life of critically ill patients.8 out of 9 studies showed that CP therapy was highly beneficial in treatment of COVID- 19, and 1 study documented evidence of adverse events. Another study conducted in 6 critically ill end stage COVID-19 patients showed that CP therapy can significantly lower viral RNA content and discontinue viral shedding but cannot improve mortality if not administered in the early stages of disease, since 5 out of 6 patients eventually died. Conclusion: The Convalescent Plasma therapy can be a promising intervention in management of COVID-19 patients in the current scenario. More clinical trials and randomised controlled trials must be conducted to further optimise the dosage, and timing of optimal administration since onset of symptoms. Significant adverse effects of the therapy also needs to be monitored.

Keywords: COVID-19; TREATMENT; CONVALESCENT PLASMA.